Top Markets
#1 Black Phoenix Black Phoenix +736.22%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.77%
#3 Wrapped STX (Velar) Wrapped STX (Velar) +17.16%
#4 Verus Coin Verus Coin +14.55%
#5 Gas Gas +10.64%
#6 Akedo Akedo +8.92%
#7 MetaDAO MetaDAO +7.62%
#8 Ontology Ontology +5.43%
#9 Ontology Gas Ontology Gas +5.36%
#10 wojak wojak +5.16%
Coin of the day
Black Phoenix Black Phoenix
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
UniQure N.V. UniQure N.V.

UniQure N.V.

QURE
Classifica tra le azioni #4587
uniQure N.V. develops treatments for patients suffering from rare and other... uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Prezzo delle azioni
$50.67
Capitalizzazione di mercato
$3.51B
Variazione (1 giorno)
-0.75%
Variazione (1 anno)
220.87%
Paese
NL
Scambia UniQure N.V. (QURE)

Categoria

Healthcare
Ricavi di UniQure N.V. (QURE)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di UniQure N.V., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per UniQure N.V. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH